-
Gedeon Richter and Myovant Sciences Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
in News, Press Releases on31 March 2020 Budapest, Hungary and Basel, Switzerland – Myovant Sciences (NYSE:MYOV), a healthcare company focused on developing innovative…
0 -
Richter announces the acquisition of Finox Holding
in News, Press Releases on30 June 2016 Richter announces the acquisition of Finox Holding for a consideration of CHF190 million. Finox Holding, a…
-
Allergan and Richter Announce Positive Phase III Results for Ulipristal Acetate 5 and 10 mg in the Treatment of Uterine Fibroids
in News, Press Releases onDUBLIN, Ireland and BUDAPEST, Hungary – 9 May 2016, — Allergan Plc (NYSE: AGN) and Gedeon Richter Plc. today announced positive…
-
European Commission approves Esmya® 5 mg for intermittent treatment in the long term management of Uterine Fibroids (myomas)
in News, Press Releases onBudapest, Hungary – 28 May 2015 – Gedeon Richter Plc. (“Richter”) announces that the European Commission (EC) has granted approval…
-
European Commission approves Esmya® Type II variation, allowing a repeated course of 3-month treatment for uterine fibroids
in News, Press Releases onBudapest, Hungary, 27 January 2013: Gedeon Richter Plc. (“Richter”) announces that Esmya® 5 mg tablets (ulipristal acetate) is now licensed…
-
European Commission approves Esmya® for the pre-operative treatment of uterine fibroids (myomas)
in News, Press Releases onBudapest, Hungary – 27 February 2012 – Gedeon Richter Plc. (“Richter”) announces today that the European Commission (EC) has granted…
-
PEARL I and II studies published in New England Journal of Medicine confirm the efficacy of Esmya® (ulipristal acetate) for the pre-operative treatment of uterine fibroids (myomas)
in News, Press Releases onGeneva, Switzerland – 2 February 2012 – PregLem, the wholly owned subsidiary of Gedeon Richter, announces full results of PEARL…
-
Richter announces that PregLem, its wholly owned subsidiary, receives positive EMA/CHMP opinion for Esmya® for the pre-operative treatment of uterine fibroids (myomas)
in News, Press Releases onBudapest, Hungary – 16 December 2011 – Gedeon Richter Plc. (“Richter”) announces that the Committee for Medicinal Products for Human…
-
Richter and Watson Announce Exclusive License Agreement for Esmya™
in News, Press Releases onBUDAPEST, HUNGARY and MORRISTOWN, New Jersey – 16 December, 2010 — Gedeon Richter Plc. (“Richter”) and Watson Pharmaceuticals, Inc. (NYSE:…
-
Richter Announces the Acquisition of PregLem
in News, Press Releases onRichter announces the Acquisition of PregLem for an initial cash consideration of CHF150 million (€114 million) and further milestone payments…
Home / News